BeiGene's TYK2 inhibitor starts clinical trials in China

Recently, according to the Insight database, BeiGene registered and started the clinical trial of the TYK2 inhibitor BGB-23339 for the first time in China

From: Insight Database applet

TYK2, a member of the JAK kinase family, functions as a key regulator of cytokine signaling pathways in a variety of immune-mediated diseases, including psoriasis and inflammatory bowel disease

BGB-23339 is a potent and highly selective investigational tyrosine kinase 2 (TYK2) allosteric inhibitor targeting the regulatory pseudokinase (JH2) domain of TYK2

A Phase 1 clinical trial of BGB-23339 is expected to enroll as early as September 2021, with plans to enroll 115 healthy subjects in Australia and China

Overview of the Global Indication Development of the BGB-23339 Project

From: Insight Database Global New Drug Module (http://db.

At present, in addition to BeiGene, Bristol-Myers Squibb and Pfizer have also launched clinical trials of TYK2 selective inhibitors in China

Among domestic companies, Nuocheng Jianhua has developed two TYK2 inhibitors, ICP-332 and ICP-488, both of which have been approved for clinical use; Hangzhou Gaoguang Pharmaceutical’s TLL-018 has also been launched for rheumatoid arthritis and ulcerative colitis Phase II clinical trials

Domestic enterprise TYK2 inhibitor project

From: Insight database applet (http://db.

Note: The original text has been deleted